Using syngeneic models, we and others demonstrated that the anti-tumor efficacy of targeting CD47 requires both innate and adaptive immune activation for breast and colorectal cancer, melanoma, and B cell lymphomas [41,43,47,48]. The gene discussed is CD47; the disease is neoplasm.